A Failed Strategy for an Effective Bladder Cancer Drug A Failed Strategy for an Effective Bladder Cancer Drug
When the number of doses of BCG for high-grade non-muscle invasive bladder cancer was cut, outcomes were inferior in a randomized clinical trial.Medscape Medical News
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Urology & Nephrology